Objective: The aim of this study was to evaluate the relationship between computed tomography assessed lobe-based lung parameters and the clinical outcomes of patients with chronic obstructive pulmonary disease (COPD), including the frequency of exacerbation and annual change in forced expiratory volume in 1 second (FEV₁).

Patients and methods: We studied 65 patients with COPD. We reconstructed computed tomography images to trace the bronchial tree from right B1 to B10 and created 3 cm circle images around the airways exactly perpendicular to the airway axis in the central, middle, and peripheral zones of the bronchi. The number of airways and vessels, airway inner diameter and area of emphysema in the circles were calculated for each segment. Then, we analyzed the relationships between the lobe-based image parameters and the frequency of exacerbation and annual decline in the FEV₁. In addition, we assessed the effects of proximal airway lumen-obliterated emphysema (ALOE) on these clinical features.

Results: The airway diameter was not associated with the frequency of exacerbation or annual decline in FEV₁. Among the structural parameters, lower lobe emphysema was most associated with the frequency of exacerbation. The reductions in the number of airways and vessels in total lobe were associated with the annual decline in FEV₁. The subgroup of patients with ALOE demonstrated lower FEV₁ and more frequent exacerbation than those without ALOE.

Conclusion: Lower lobe emphysema predicts frequent COPD exacerbation, whereas the annual decline in FEV₁ is associated with the number of airways and vessels in total lobe.

Keywords: chronic obstructive pulmonary disease, computed tomography, acute exacerbation, pulmonary function tests, low attenuation area

Introduction

The clinical course of chronic obstructive pulmonary disease (COPD) is considerably heterogeneous, with a portion of patients experiencing frequent exacerbation and a rapid decline in the forced expiratory volume in 1 second (FEV₁).¹,² Acute exacerbation accelerates the decline in the lung function and is associated with an impaired quality of life and higher mortality.³,⁴,⁵ Therefore, the frequency of exacerbation and annual decline in FEV₁ are key parameters for COPD treatment. The ability to predict which patients are at greater risk of exacerbation and rapid decline in FEV₁ would be beneficial for targeting these patients for the early introduction of preventive therapy.

Following advances in computed tomography (CT), it is becoming an important tool for evaluating COPD. Quantitative CT measurements of the degree of emphysema and...
the airway wall thickness have been explored to identify sub-
groups of patients with COPD who experience more frequent
exacerbation.7 However, more detailed lung parameters of
the upper, lower, and/or total lobes have not been previously
evaluated in relation to the clinical outcomes of COPD. In a
previous study, we evaluated the airway diameter and lung
parameters in 3 cm circles along the airways in the right B1
to B10 bronchi from the level of the segmental bronchi to
the peripheral airways 2 cm from the pleura by CT using
curved multi-planar reconstruction (MPR) of the airways
with an ultra-high resolution (UHR) mode and an interactive
reconstruction algorithm.8 These segment-based analyses of
lung parameters enabled us to study the relationship between
lobe-based lung parameters and longitudinal clinical outcomes
of COPD. In a previous study, we observed significant asso-
ciation of lower lobe emphysema with the progression of
airflow limitation stage.8 In addition, by tracing the airways,
we previously identified a distinctive type of emphysema,
airway lumen-obiterated emphysema (ALOE), with complete
luminal occlusion of the proximal conducting airway accom-
panied by sub-segmental confluent emphysema separated by
clear border from the surrounding segments.8 The obliterated
airway could be traced into the extensively destructed area. In
contrast to the confluent centrilobular emphysema, this type
of emphysema was typically observed in lower lobes.

Based on these previous observations, we studied to
examine whether lobe-based lung parameters, such as the air-
way diameter, percentage of low attenuation areas (%LAA),
and number of airways and vessels are associated with the
frequency of exacerbation and annual decline in FEV1 in
patients with COPD. Second, we stratified COPD patients
with and without ALOE and compared the above clinical
features between the two groups.

Methods
Patients
We previously studied 70 Japanese males with COPD who
underwent UHR-CT for an evaluation of emphysema between
March 1 and October 31, 2012.7 We checked medical records
and inquired about episodes of exacerbation during the previ-
ous 1 year prior to that study until October 31, 2014. Among
the 70 subjects, we studied 65 patients who had records of at
least two sets of pulmonary function tests (PFTs) performed
1 year after the first PFT. If PFTs were recorded for more
than 2 years, the mean annual change in FEV1 was calculated.
Subjects exhibiting a history of allergies, episodic whee-
zing, or a high serum IgE level were excluded. Patients were
treated and cared for according to the Japanese guidelines
of COPD.9 Patients were all ex-smokers at the start of this
study. Exacerbation was defined as the number of respira-
tory exacerbations requiring treatment with antibiotics and/
or steroids. We recorded number of level I exacerbations:
treated at home; and number of level II/III exacerbations:
requiring hospitalization or leading to respiratory failure.10
The institutional Review Board of Saitama Cardiovascu-
lar and Respiratory Center approved this study (IRB No
2011002), and all subjects provided their written informed
consent prior to participation in the study.

PFTs
The PFTs were performed using a CHESTAC8800 device
(Chest MI Corp., Tokyo, Japan). PFT data included measure-
ments of forced vital capacity and FEV1. The methods for
obtaining the spirometric measurements and their predicted
values were derived from the guidelines for PFTs issued
by the American Thoracic Society/European Respiratory
Society and Japanese Respiratory Society.11,12 Spirometry
was performed before and 30 minutes after the inhalation of
200 µg of salbutamol, and the data obtained after salbutamol
inhalation were used for the evaluation.

Spirometry was to be done at the start of the study and
every year during the study.

CT data acquisition and reconstruction
We used the image data of 65 subjects assessed in our previ-
ous study.8 In brief, a multi-slice CT scanner (256 slices,
Brillance iCT; Philips Healthcare, Cleveland, OH, USA)
was used. The CT scans were acquired with the follow-
ing parameters: tube voltage: 120 kVp; tube current-time
product: 200 mAs; detector configuration: 20×0.625 mm col-
limination with UHR mode; reconstruction section thickness;
0.67 mm, helical mode with 0.55 pitch; gantry rotation time:
0.4 seconds; display field of view: 200 mm. In order to
reduce image noise, all images were reconstructed from UHR
data using an interactive reconstruction algorithm (iDose4;
Philips Healthcare).13–15 The patients were asked to inhale
depthly and hold for several moments, after which the scans
were obtained. The reconstructed data were transferred
to a workstation (Brillance™ Workspace Portal; Philips
Healthcare) and then reconstructed into the curved MPR
of the airway.

Analysis of the airway structures
We calculated CT image parameters obtained in our previous
study9 for the total lobe (B1–B10), upper lobe (B1–B3) and
lower lobe (B6–B10). In brief, we previously obtained the
7,800 data sets (inner diameter, airway and vessel number, and %LAA) from 1,950 circle images (30 points in 10 right bronchial trees) in 65 COPD patients in a partially different manner from that applied in our previous study,4 ie, they were calculated for each lobe. In brief, the right B1 to B10 bronchial trees were analyzed. The bronchial tree was traced from the peripheral point of the airway within 2 cm from the pleura to the entrance of the segmental bronchus. We designated the point in the airway 2 cm from the pleura as the peripheral zone, the point 2 cm from the entrance of the segmental bronchus as the central zone, and the point half-way between these two points as the middle zone. At each point, we reconstructed images perpendicular to the axis of the airway and set a 3 cm circle with the selected airway in the center. Using a method previously reported with minor modifications, %LAA was calculated in the circle.16–18 The number of airways as well as arteries and veins (vessels) in the circle and the inner diameter of the airway at the center of the circle was measured.

**ALOE and clinical outcomes**

ALOE is characterized by proximal airway lumen occlusion and sub-segmental air-trapped emphysema.8 Since it can be recognized as an extensively destructed area clearly separated from next segments, the numbers of segments with ALOE were counted and their relationships to the %FEV\textsubscript{1}, annual change of FEV\textsubscript{1}, and frequency of exacerbation were analyzed.

### Statistical analysis

The statistical analyses were performed using Prism 5 software program (GraphPad Software, Inc., La Jolla, CA, USA), and the data are expressed as the mean ± standard deviation. Spearman’s rank test was used to assess the correlations between the imaging data and the clinical parameters including the frequency of exacerbation and annual decline in FEV\textsubscript{1}. The Mann–Whitney U-test was used to compare parameters between the subjects with and without ALOE. A P-value of less than 0.05 was considered to be statistically significant.

### Results

#### Clinical characteristics

The subjects’ demographics are presented in Table 1. These data are stratified by the presence of ALOE. Of the total 65 subjects, 26 (40%) subjects had ALOE in one or more bronchi. There were no differences in age, the smoking-index, annual change in FEV\textsubscript{1} or airway reversibility between the groups with and without ALOE. However, the subjects with ALOE had lower body mass index (18.9±3.1 kg/m\textsuperscript{2} versus (vs) 21.5±3.5 kg/m\textsuperscript{2}, P=0.006), forced vital capacity (75.4±14.1 vs 89.2±23.1, % predicted, P=0.009) and FEV\textsubscript{1} (43.4±18.3 vs 76.0±30.6, % predicted, P<0.001) values than the subjects without ALOE. Inhaled corticosteroids were used in 50.8% of total patients, and the patients with ALOE used more inhaled corticosteroids and long-acting muscarinic antagonists than those without ALOE. At the

| Table 1 | Demographic data of the subjects stratified for presence of airway-lumen obliterated emphysema |
|---------|-----------------------------------------------------------------------------------------------|
|         | Total | ALOE, yes | ALOE, no | P     |
| Number  | 65    | 26        | 39       | NS    |
| Age     | 70.8 (6.4) | 70.5 (5.9) | 71.0 (6.9) | NS |
| Pack-years | 76.2 (34.7) | 76.1 (33.0) | 76.3 (36.3) | NS |
| Body mass index | 20.5 (3.6) | 18.9 (3.1) | 21.5 (3.5) | P=0.006 |
| FVC, % predicted | 83.7 (21.0) | 75.4 (14.1) | 89.3 (23.1) | P=0.009 |
| FEV\textsubscript{1}, % predicted | 62.9 (30.7) | 43.4 (18.3) | 76.0 (30.6) | P<0.001 |
| FEV\textsubscript{1} change, mL/yr | −34.3 (38.7) | −32.0 (36.6) | −35.7 (40.5) | NS |
| FEV\textsubscript{1}, reversibility, % | 4.9 (7.3) | 5.8 (7.0) | 4.4 (7.6) | NS |
| Treatments | | | | |
| Inhaled corticosteroids | 50.8% | 69.2% | 38.5% | P=0.023 |
| Long-acting β-agonist | 56.9% | 73.1% | 48.7% | NS |
| Long-acting muscarinic antagonists | 73.8% | 84.6% | 66.7% | P=0.018 |
| Treatments for exacerbations | | | | |
| Antibiotics | 100% | 100% | 100% | NS |
| Systemic Corticosteroids | 20.8% | 29.2% | 12.5% | NS |

**Notes:** P, significance of difference between groups with or without ALOE was analyzed by Mann–Whitney U-test. Means (standard deviation) are expressed for number, age, body mass index, FVC, FEV\textsubscript{1}, changes of FEV\textsubscript{1} and reversibility of FEV\textsubscript{1}. Percentages of the drugs used are expressed for the daily treatments and treatments for exacerbations.

**Abbreviations:** ALOE, airway lumen-obliterated emphysema; FVC, forced expiratory volume; FEV\textsubscript{1}, forced expiratory volume in 1 second; yr, year; NS, not significant.
time of COPD exacerbation, systemic corticosteroids were used in 20.8% of cases.

Lung parameters and frequency of COPD exacerbation
The mean overall exacerbation frequency was 0.67±0.85 exacerbations per year and exacerbation that needed hospitalization was 0.21±0.37 per year. There were no correlations between the post-bronchodilator airway diameter or number of airways/vessels and the frequency of exacerbation. However, the %LAA of the total lobe correlated with the frequency of exacerbation ($r=0.452$, $P<0.001$), with the lower-lobe %LAA being most correlated with the incidence of exacerbation ($r=0.499$, $P<0.001$) (Figure 1).

Lung structures and annual change in FEV₁
There were no correlations between the post-bronchodilator airway diameter or %LAA and the annual change in FEV₁. However, the mean numbers of airways and vessels in the circles of total lobe, but not upper or lower lobes, weakly correlated with the annual change in FEV₁ ($r=0.259$, $P=0.047$ and $r=0.293$, $P=0.024$, respectively). The heterogeneity in the number of airways and vessels was observed by curved MPR images of airways. Figure 2 shows two representative phenotypes of COPD with less preserved (Figure 2A) or more preserved (Figure 2B) airway/vessel structures along the airways. To show heterogeneity in the number of airways/vessels in relation to extent of emphysema, we plotted mean numbers of airway/vessel to the mean %LAA in 3 cm circles in total lobe (Figure 3). The figure shows that correlations between number of airways/vessels and %LAA were weak ($r=-0.276$, $P=0.026$; $r=-0.369$, $P=0.002$, respectively), and there were significant heterogeneities in the amount of airways and vessels to the extent of emphysema. We stratified the subgroups of patients who had more preserved airways/vessels above on or on the line of linear regression lines and less preserved groups of patients whose plots were under the lines. The subgroup of patients who had more preserved vessels along airways (Figure 3Ab, n=29) had smaller decline of FEV₁ compared to those (Figure 3Aa, n=36) with less preserved vessels ($-21.7±33.1$ mL/yr vs $-43.8±32.5$ mL/yr, respectively, $P=0.015$). The annual declines of FEV₁ in patients with more or less preserved airways were $-26.4±44.7$ mL/yr (Figure 3Bb, n=29) vs $-40.6±32.5$ mL/yr (Figure 3Ba, n=36), respectively ($P=0.062$).

Clinical features of ALOE
The curved MPR images of airways showed a distinctive type of emphysema; ALOE. ALOE was observed in 60 segments of 26 patients (eight in upper lobe, 19 in middle lobe, and 33 in lower lobe). Of note, 14 (23.3%) cases of ALOE were observed in B7. The patients with ALOE had lower post-bronchodilator %FEV₁ than those without ALOE (48.5%±21.2% vs 76.0%±30.6%, $P<0.001$, Figure 4A). However, the presence of ALOE had no correlation to the annual decline in FEV₁ (Figure 4B). The subjects with ALOE demonstrated a greater frequency of exacerbation than the COPD subjects without ALOE (1.05±1.12 per year vs 0.42±0.48 per year, respectively, $P<0.001$) (Figure 5).

Discussion
In the present study, the frequency of COPD exacerbation was most associated with lower lobe emphysema, whereas the annual decline in FEV₁ was associated with the numbers of airways and vessels. The patients with ALOE exhibited severe airflow limitations and more frequent episodes of exacerbation than the patients without ALOE. These data suggest that specific CT-assessed lung structures are associated with specific longitudinal outcomes of COPD.

![Figure 1](image1.png)

**Figure 1** Percentages of low attenuation area (%LAA) and frequency of COPD exacerbation.

**Notes:** Panels (A–C) demonstrate the relationship between frequency of COPD exacerbation and %LAA in total lobe (right B1–B10, [A]), upper lobe (right B1–B3, [B]) and lower lobe (right B6–B10, [C]). Each %LAA value shows mean value of 3 cm circle images exactly perpendicular to the axis of the airways at central zone (2 cm from the entrance of segmental bronchus), peripheral zone (2 cm from the pleura), and middle zone (halfway point of central and peripheral points) of each bronchus.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.
In a previous study, we reported that the post-bronchodilator %FEV₁ was most associated with the mean airway diameter and partially associated with the middle zone %LAA and the number of peripheral zone airways. In the current study, the airway diameter was not associated with the frequency of COPD exacerbation or the annual change in FEV₁. These data may partially explain why COPD stage which is defined by %FEV₁, is not well associated with the frequency of exacerbation.

In contrast, this study showed that emphysema was associated with the frequency of exacerbation. The result is in accordance with previous observations in the COPDGene study that demonstrated emphysema and airway wall thickness to be risk factors for COPD exacerbation. Compared to that study,
the present study included a small sample size and did not analyze airway wall thickness. However, we further revealed that lower lobe emphysema was more important compared to the other lung structures. One of the potential explanations for the association between frequency of exacerbation and lower lobe emphysema is the difficulty in airway clearance in the lower lobe. The airways are supplied with alveolar surfactant and surfactant is thought to be important for small airway potency and mucociliary clearance. The reduced supply of surfactant and the reduced exhaled airflow resulting from upstream emphysema makes sputum clearance more difficult in the lower lobe vs the upper lobe.

Previous reports showed that emphysema is associated with rapid decline in FEV\textsubscript{1}. We further demonstrated in this study that reduced numbers of airways/vessels along the airways rather than emphysema itself were associated with annual decline of FEV\textsubscript{1}. Emphysema is preceded by the reduction of airways, but we found heterogeneity in the numbers of airways/vessels to the extent of emphysema. Airways and vessels are connected by “septal fibers” as reported by Weibel, and we clearly demonstrated interstitial connections among airways and vessels in our previous study. One potential explanation for the results of this study is that subjects with preserved airways/vessels might be more resistant to the mechanical stress from repeated air trapping.

Finally, the presence of ALOE was associated with severe airflow limitation and the frequency of exacerbation. It is possible that sub-segmental air trapping in the lower lobe interferes with the movement of the diaphragm. However, further studies are needed about the nature and clinical significance of ALOE.

There are several limitations associated with this study that should be noted. The number of subjects was limited, such that some of the parameters may have been found to be significant in a much larger study. However, we believe that the current study successfully demonstrated the relative significance of the lung parameters. The results of the present study do not necessarily contradict the reported effects of long-acting bronchodilators in preventing COPD exacerbation, because we examined the airway diameter after the use of a short-acting bronchodilator, and did not assess the effects of full-day airway potency. In addition, the effects of daily treatments cannot be assessed because of the observational study design.

In conclusion, in spite of several limitations, lobe-based CT assessment of airways and lung structures along the airway can provide useful information about lung function and clinical outcomes of COPD. Presence of lower lobe...
emphysema and ALOE can be used to define subgroups of COPD patients who experience more exacerbations. These patients need special health care because sputum clearance is much more difficult in lower lobes than in upper lobes. In addition, reduction of airways/vessels occurs in the very early stages of COPD, recognizing these changes at an early stage is important for improving the clinical outcome.

Disclosure
The authors have no conflict of interest to disclose.

References
1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
2. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192.
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
4. Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(5):446–452.
5. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422.
6. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931.
7. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: Associated radiologic phenotypes. Radiology. 2011;261(1):274–282.
8. Kurashima K, Hoshi T, Takaku Y, et al. Changes in the airway lumen and surrounding parenchyma in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:523–532.
9. Japanese Respiratory Society. [Guideline for diagnosis and management of COPD (chronic obstructive pulmonary disease). The Third Edition: therapy and management]. Nihon Kokyuki Gakkai Zasshi. 2009;Suppl Copd:70–144. Japanese.
10. Cili BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
11. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
12. Japanese Respiratory Society. [The predicted values of spirometry and arterial blood gas analysis in Japanese]. J Jpn Resp Soc. 2001;39: Appendix. Japanese.
13. Noël PB, Fingerle AA, Renger B, et al. Initial performance characterization of a noise-suppressing reconstruction algorithm for MDCT. AJR Am J Roentgenol. 2011;197(6):1404–1409.
14. Miéville FA, Giudinchet F, Brunelle F, Bochud FO, Verdun FR. Iterative reconstruction methods in two different MDCT scanners: Physical metrics and 4-alternative forced-choice detectability experiments – a phantom approach. Phys Med. 2013;29(1):99–100.
15. Rajah P, Schoenhagen P, Mehta D, et al. Low-dose, wide-detector array thoracic CT angiography using an iterative reconstruction technique results in improved image quality with lower noise and fewer artifacts. J Cardiovasc Comput Tomogr. 2012;6(3):205–213.
16. Sakai N, Mishima M, Nishimura K, Itoh H, Kunoo K. An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest. 1994;106(5):1319–1325.
17. Nakano Y, Sakai H, Muro S, et al. Comparison of low attenuation areas on CT between inner and outer segments of the lung in COPD patients: incidence and contribution to lung function. Thorax. 1999;54(5):384–389.
18. Mishima M, Oku Y, Kawakami K, et al. Quantitative assessment of the spatial distribution of low attenuation areas on X-ray CT using texture analysis in patients with chronic pulmonary emphysema. Front Med Biol Eng. 1997;8(1):19–34.
19. Pettenazzo A, Jobe A, Humme J, Seidner S, Ikegami M. Clearance of surfactant phosphatidylcholine via the upper airways in rabbits. J Appl Physiol (1988). 1988;65(5):2151–2155.
20. Macklem PT. Airway obstruction and collateral ventilation. Physiol Rev. 1971;51(2):368–436.
21. Rensch H, von Seefeld H. Surfaktant – mucus interaction. In: Robertson B, van Golde LM, Batenburg JJ, editors. Pulmonary Surfactant. Elsevier; 1984:203.
22. Morgenroth K. Morphology of bronchial lining layer and its alternation in IRDS, ARDS and COLD. Eur J Respir Dis. 1985;142(7–18).
23. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44–52.
24. Tashkin DP, Celli B, Senn S, et al. A four-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
25. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575.
26. Weibel ER. It takes more than cells to make a good lung. Am J Respir Crit Care Med. 2013;187(4):342–346.
27. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.